公开(公告)号：EP4438037A1

公开(公告)日：2024-10-02

申请号：EP24179001.3

申请日：2022-01-27

Applicant: Priothera SAS ,  Priothera Limited

Inventor： BUCHER, Christoph ,  DERTSCHNIG, Simone

IPC: A61K31/00 ,  A61K9/00 ,  A61K31/137 ,  A61K31/397 ,  A61K31/4245 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61K31/436 ,  A61K31/519 ,  A61K31/5377 ,  A61K38/13 ,  A61K31/13

CPC classification number: A61K31/137 ,  A61K31/00 ,  A61K31/397 ,  A61K31/4245 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61K31/5377 ,  A61K31/13 ,  A61K31/436 ,  A61K31/519

Abstract: The present invention relates to S1P receptor modulators, preferably mocravimod, for use in treating patients suffering from acute myelogenous leukemia (AML) and who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The invention relates in particular to methods of treating AML in subjects undergoing HSCT, wherein said method comprises daily administering an efficient amount of S1P receptor modulator, preferably mocravimod, to said subject in need thereof, for at least 6 months, preferably at least 12 months.

公开(公告)号：EP4431493A1

公开(公告)日：2024-09-18

申请号：EP22894817.0

申请日：2022-11-16

Applicant: Shenzhen Bay Laboratory ,  Peking University Shenzhen Graduate School

Inventor： ZHU, Zhendong ,  XU, Zhengshuang ,  LI, Ting ,  CHE, Chao ,  REN, Xingye ,  CHEN, Sigui ,  ZHANG, Jiayin ,  ZHANG, Ben ,  YANG, Qi ,  ZHANG, Chuanbing ,  YANG, Zhen

IPC: C07D205/04 ,  C07D213/30 ,  C07D401/02 ,  C07D401/14 ,  C07D409/02 ,  C07D403/14 ,  C07C65/26 ,  C07C63/49 ,  A61K31/44 ,  A61K31/4025 ,  A61K31/397 ,  A61K31/404 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P31/22

CPC classification number: A61K31/397 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/506 ,  A61P19/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P39/00 ,  C07C63/49 ,  C07C65/26 ,  C07D205/04 ,  C07D213/30 ,  C07D213/56 ,  C07D213/75 ,  C07D401/02 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D409/02 ,  C07D409/14 ,  C07D417/14

Abstract: A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis, especially nasopharyngeal carcinoma. The present invention further provides a small molecule inhibitor against nasopharyngeal carcinoma, and/or a pharmaceutical composition comprising same, capable of being used for treating nasopharyngeal carcinoma.

公开(公告)号：EP3815684B1

公开(公告)日：2024-09-04

申请号：EP20201864.4

申请日：2013-06-28

IPC: A61K31/232 ,  A61K31/397 ,  A61K45/06 ,  A61P9/10 ,  A61P9/00 ,  A61P3/04 ,  A61P3/06 ,  A61P9/04 ,  A61P9/06 ,  A61P43/00

CPC classification number: A61K31/397 ,  A61K31/232 ,  A61P3/04 ,  A61P3/06 ,  A61P43/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10

公开(公告)号：EP3454838A1

公开(公告)日：2019-03-20

申请号：EP17723657.7

申请日：2017-05-07

Applicant: Adamed Pharma S.A.

Inventor： CIEPLUCHA, Agnieszka

IPC: A61K9/16 ,  A61K9/20 ,  A61K31/00

CPC classification number: A61K9/1635 ,  A61K9/1694 ,  A61K9/2027 ,  A61K9/2077 ,  A61K31/397 ,  A61K31/505 ,  A61K45/06 ,  A61P3/06 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising rosuvastatin and ezetimibe for oral administration in the form of a blend of a first component comprising rosuvastatin or a pharmaceutically acceptable salt thereof, wherein the component is dry-granulated, a second component comprising ezetimibe or a pharmaceutically acceptable salt thereof, wherein the component is wet-granulated, and an optionally extragranular phase component, characterized in that the pharmaceutical composition is free from any rosuvastatin stabilizers, and d 90 value for granules of the first component is 800 µm or less. The invention relates also to an uncoated tablet comprising the composition, and a method of manufacturing the composition.

公开(公告)号：EP2888008B1

公开(公告)日：2018-12-26

申请号：EP13831336.6

申请日：2013-08-19

Applicant: Merck Sharp & Dohme Corp.

Inventor： APGAR, James, M. ,  BIFTU, Tesfaye ,  CHEN, Ping ,  FENG, Danqing ,  HICKS, Jacqueline, D. ,  KEKEC, Ahmet ,  LEAVITT, Kenneth, J. ,  LI, Bing ,  SEBHAT, Iyassu ,  QIAN, Xiaoxia ,  WEI, Lan ,  WILKENING, Robert, R. ,  WU, Zhicai ,  ARASAPPAN, Ashok

IPC: C07D471/04 ,  C07D519/00 ,  A61P3/10 ,  A61K31/4184 ,  A61K31/415 ,  A61K31/454

CPC classification number: C07D471/04 ,  A61K31/19 ,  A61K31/366 ,  A61K31/397 ,  A61K31/437 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  C07C53/18 ,  C07D519/00 ,  A61K2300/00

Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

公开(公告)号：EP2127650B1

公开(公告)日：2018-12-05

申请号：EP09011657.5

申请日：2005-06-10

Applicant: FOB Synthesis, Inc.

Inventor： Choi, Woo-Baeg ,  Kowalik, Ewa

IPC: A61K31/397 ,  C07D477/14

CPC classification number: C07D477/14 ,  A61K31/397 ,  A61K45/06 ,  Y02P20/55 ,  A61K2300/00

Abstract: The present invention provides ²-methyl carbapenem compounds or pharmaceutically acceptable salts thereof, wherein: R 1 is hydrogen or methyl; P is hydrogen or hydroxyl; M is H or a group such that CO 2 M is a carboxylic acid, a carboxylate anion, a pharmaceutically acceptable ester group, or a carboxylic acid protected by a protecting group; and Y is -(CH 2 ) n -A, wherein n is 0-4 and A is -CN, -OR 2 , -SR 2 , -N(R 2 ) 2 , CO 2 R 2 , C(=O)-N(R 2 ), -C(=O)-NR 2 SO 2 N(R 2 ) 2 , NR 2 SO 2 N(R 2 ) 2 , NH-C(=NR 2 )-N(R 2 ) 2 , -S-C(=NR 2 )-N(R 2 ) 2 , wherein each R 2 is independently H or C 1 -C 4 alkyl and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of ²-methyl carbapenems which arc useful as antibacterial agents.

公开(公告)号：EP3150577B1

公开(公告)日：2018-08-29

申请号：EP16002350.3

申请日：2012-09-27

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Naganawa, Atsushi ,  Kusumi, Kensuke ,  Otsuki, Kazuhiro ,  Sekiguchi, Tetsuya ,  Kakuuchi, Akito ,  Shinozaki, Koji ,  Yamamoto, Hiroshi ,  Nonaka, Shigeyuki

IPC: C07D205/04 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P11/00 ,  A61P25/00 ,  A61P43/00 ,  C07D207/10 ,  C07D207/12 ,  C07D211/48

CPC classification number: A61K31/445 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  C07D205/04 ,  C07D207/12 ,  C07D207/16 ,  C07D211/48 ,  C07D211/52 ,  C07D401/12 ,  C07D405/12

Abstract: The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P 2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P 2 -mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

公开(公告)号：EP3355928A1

公开(公告)日：2018-08-08

申请号：EP16778294.5

申请日：2016-09-30

Applicant: Grace GmbH

Inventor： HOEFER, Hans Hermann ,  MONSUUR, Frederik Hendrik ,  PAULY, Thomas ,  CHOUDHARI, Yogesh ,  LOBMANN, Korbinian ,  RADES, Thomas

IPC: A61K47/10 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  A61K9/14 ,  A61K31/00

CPC classification number: A61K9/143 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/00 ,  A61K31/192 ,  A61K31/397 ,  A61K47/10 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  C01B33/18 ,  C01P2004/50 ,  C01P2004/61 ,  C01P2006/12 ,  C01P2006/14 ,  C01P2006/16 ,  C01P2006/82

Abstract: Particles are disclosed. Methods of making and using the particles are also disclosed.

公开(公告)号：EP3351238A1

公开(公告)日：2018-07-25

申请号：EP16845742.2

申请日：2016-09-14

Applicant: ALAYA (SHANGHAI) BIOSCIENCE CO., LTD

Inventor： TAN, Yun ,  WANG, Gang

IPC: A61K9/16 ,  A61P31/04 ,  A61P31/10 ,  A61K31/19

CPC classification number: A61K9/1617 ,  A61K9/107 ,  A61K9/16 ,  A61K31/16 ,  A61K31/19 ,  A61K31/397 ,  A61K47/14 ,  A61K47/542 ,  A61K2300/00 ,  A61P31/04 ,  A61P31/10

Abstract: Non-vesicular nanoparticles which have antibacterial activity and are made from a C8-C28 fatty acid or a derivative thereof, a surfactant and an optional lipid.

公开(公告)号：EP2877185B1

公开(公告)日：2018-05-23

申请号：EP13823863.9

申请日：2013-07-26

Applicant: Biogen MA Inc.

Inventor： GUCKIAN, Kevin ,  KUMARAVEL, Gnanasambandam ,  MA, Bin ,  MI, Sha ,  SHAO, Zhaohui ,  SUN, Lihong ,  TAVERAS, Arthur ,  WANG, Deping ,  XIN, Zhili ,  ZHANG, Lei

IPC: C07D213/79 ,  C07C47/575 ,  A61K31/683 ,  A61P19/02

CPC classification number: A61K31/662 ,  A61K31/196 ,  A61K31/397 ,  A61K31/435 ,  A61K31/445 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5375 ,  A61K31/55 ,  A61K45/06 ,  C07B2200/07 ,  C07C229/46 ,  C07C229/48 ,  C07C233/47 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2602/26 ,  C07D205/04 ,  C07D207/08 ,  C07D207/16 ,  C07D211/34 ,  C07D211/62 ,  C07D213/79 ,  C07D213/80 ,  C07D215/20 ,  C07D223/06 ,  C07D265/30 ,  C07D401/04 ,  C07D401/06 ,  C07F9/38 ,  C07F9/3808

Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).